Alzheimer’s drugs Market Size, Share, Growth Report 2032

Alzheimer’s drugs Market: Industry Prospective

The global Alzheimer’s drugs market was worth around USD 6,429.5 billion in 2021 and is estimated to grow to about USD 9276.3 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.3 percent over the forecast period. The report analyzes the Alzheimer’s drugs market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Alzheimer’s drugs market.

Alzheimer’s drugs Market: Overview

Alzheimer’s drugs are used in the treatment of Alzheimer which is a rare disease that is increasing in incidence over the past few years. This neurodegenerative disorder causes brain cells to die and this results in mostly loss of memory and a decline in functionality of the brain and other organs of the body.

The increasing prevalence of Alzheimer’s is expected to be the major factor driving Alzheimer’s drugs market growth. Apart from this increasing awareness regarding Alzheimer’s and rising research and development for the treatment of the disease are expected to influence Alzheimer’s drugs market potential over the forecast period.

However, discontinuation of clinical trials for Alzheimer’s from major pharmaceutical and healthcare companies is expected to have a hindering effect on the Alzheimer’s drugs market growth.

COVID-19 Impact:

The emergence of the COVID-19 pandemic led to a major negative impact on the Alzheimer’s drugs market as diagnostic and therapeutic procedures around the world were impacted due to the decline in visits to hospitals and diagnostic centers because of lockdown restrictions imposed by various governments to curb the spread of coronavirus infections across nations. The shift of focus from other health conditions to coronavirus also had an adverse impact on the Alzheimer’s drugs market growth.

With vaccinations picking up pace and a decline in COVID cases across the world, the Alzheimer’s drugs market is anticipated to make a comeback in the post-pandemic era at a steady pace through 2028. Resumption of normal world activity and a shift of focus on other health conditions apart from COVID will drive Alzheimer’s drugs market growth at a steady pace through 2028.

Request Free Sample

Alzheimer’s drugs Market: Growth Drivers

Increasing Research and Development Activity

Advancements in pharmaceutical and healthcare industries have spawned a new wave of research and development activities across the world and this trend is the same for the Alzheimer’s drugs market as well. As the incidence of Alzheimer’s is on the rise pharmaceutical companies are focusing on the development of novel treatments to maximize their revenue potential as instances of these diseases increases on a global level.

Alzheimer’s drugs Market: Restraints

Discontinuation of Clinical Trials to Hamper Alzheimer’s drugs Market growth

Alzheimer’s has been around for quite a while now but there has been no discovery of a definite treatment for the disease and this has led to skepticism around investments in research and development for the same. This skepticism has led to the discontinuation of clinical trials for the development of Alzheimer’s drugs and hence has had a hindering effect on the global Alzheimer’s drugs market growth. This trend is expected to be prevalent over the forecast period.

Global Alzheimer’s drugs Market: Segmentation

The global Alzheimer’s drugs market is segregated based on drug class, distribution channel, and region.

By Distribution channel, the Alzheimer’s drugs market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others. The hospital pharmacies segment is projected to account for a dominant market share in the global Alzheimer’s drugs market landscape and this trend is expected to be prominent over the forecast period as well.  

Report Scope:

Recent Developments

• In December 2018 – Eli Lilly and Company a leading name in the pharmaceutical industry announced a collaboration with AC Immune to develop a new treatment for Alzheimer’s which will be done by utilizing AC Immune’s Morphomer platform.

Alzheimer’s drugs Market: Regional Landscape

North America region leads the global Alzheimer’s drugs market in terms of revenue and volume share and is projected to follow the same trend over the forecast period. The presence of key pharmaceutical and healthcare companies, rising research and development activity in the region, and increasing investments in the development of treatment for Alzheimer’s are some of the major factors that drive the Alzheimer’s drugs market potential in this region. The increasing aging population in North America is also expected to boost the incidence of Alzheimer’s and this is expected to propel the demand for Alzheimer’s drugs over the forecast period. The United States is anticipated to be the most notable market in this region through 2028. The rising prevalence of Alzheimer’s disease and increasing launches of new Alzheimer’s drugs are expected to be prominent trends driving market growth in the U.S.

Alzheimer’s drugs Market: Competitive Landscape

Some of the main competitors dominating the global Alzheimer’s drugs market include – Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited

Global Alzheimer’s drugs market is segmented as follows:

By Drug class

• Donepezil
• Galantamine
• Rivastigmine
• Memantine
• Others

By Distribution channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Stores
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa